title: Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose.
abstract: Magnesium sulfate, a biologically potent compound, given sometimes in extraordinarily high doses, is among the most commonly used pharmaceuticals in American obstetric practice. Although most clinicians are in accord regarding its value for seizure prophylaxis in the setting of preeclampsia, such unanimity is not the case regarding its role in preterm labor. Credible scientific data indicate not only a lack of efficacy, but also toxicity to susceptible fetuses when magnesium sulfate is used in the high dosages found in tocolysis. In apparent contrast, three recent clinical trials, although individually inconclusive, provide data from which a very recent meta-analysis affirms a potential role for magnesium sulfate in prophylaxis against fetal neurologic injury. Comparing outcomes from these trials, with attention to dosage, relationships are revealed that unify observations previously regarded as conflicting: Magnesium sulfate indeed may have both neuroprotective and fetal toxic effects. The better, and safer, neuroprotection seems to occur at comparatively low antenatal doses (perhaps in a range between 4 g and 10.5 g), whereas increasing dosages exceed a "therapeutic window" whereby, as with most drugs, toxic sequelae begin to accrue.
authors.affiliation: From The University of Wisconsin Medical School, Madison, Wisconsin; and the Departments of Obstetrics and Gynecology and of Pediatrics, Loyola University Medical Center, Maywood, Illinois.
authors.forename: Peter G
authors.initials: PG
authors.lastname: Pryde
authors.forename: Robert
authors.initials: R
authors.lastname: Mittendorf
mesh_terms: D000075202:Contraindications; D005260:Female; D006801:Humans; D008274:Magnesium / Q000008:administration & dosage*; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D015149:Tocolytic Agents / Q000008:administration & dosage*
chemical_list: D015149:Tocolytic Agents; D008274:Magnesium
references.citation: Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359:895–905.
references.citation: Gad SC. Drug safety evaluation. 3rd ed. Hoboken (NJ): John Wiley & Sons; 2002 p. 345.
references.citation: Crowther CA, Hiller JE, Doyle LW, Haslam RR, Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290:2669–76.
references.citation: Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque Hellot MF. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007;114:310–8.
references.citation: Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 2006;108:986–9.
references.citation: Cox SM, Sherman ML, Leveno KJ. Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol 1990;163:767–72.
references.citation: Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997;350:1517–8.
references.citation: Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:263–9.